All In Biotech

Free tool

FAERS Monitor: Steglatro

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 209803 or its brand name (Steglatro, Ertugliflozin). Reports on generic versions are filed under their own applications.

Reports

1,116

Serious

520

47% of reports

Hospitalization

328

Death reported

12

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • nausea91
  • product dose omission issue71
  • urinary tract infection66
  • vomiting65
  • fungal infection58
  • no adverse event56
  • diabetic ketoacidosis54
  • blood glucose increased51
  • dizziness49
  • diarrhoea47
  • drug ineffective41
  • product dose omission29
  • decreased appetite28
  • diabetes mellitus inadequate control28
  • fatigue26

Reports by year received

View as table
YearReports
20131
20172
2018132
2019280
202095
202181
202296
2023112
2024116
2025125
202676

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,043 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
diabetic ketoacidosisSignal5442.532.72,143
fungal infectionSignal5832.925.61,759
diabetes mellitus inadequate controlSignal2829.920.7752
product dose omissionSignal298.45.8182
urinary tract infectionSignal667.35.8355
no adverse eventSignal565.84.5221
blood glucose increasedSignal515.13.9166
product dose omission issueSignal714.63.6196
vomitingSignal652.62.164
decreased appetiteSignal282.31.619
nauseaSignal912.21.858
dizziness491.91.419
diarrhoea471.41.05
fatigue260.60.46
drug ineffective410.60.412

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.